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http://dxObjectives:We have previously demonstrated that biventricular pacing increased cardiac output within 1 hour
of weaning from cardiopulmonary bypass in selected patients. To assess the possible sustained benefit, we re-
viewed in the present study the effects of biventricular pacing on the mean arterial pressure after chest closure.
Methods: A total of 30 patients (mean ejection fraction 35% 15%, mean QRS 119 24 ms) underwent cor-
onary bypass and/or valve surgery. The mean arterial pressure was maximized during biventricular pacing using
atrioventricular delays of 90 to 270 ms and interventricular delays ofþ80 to80 ms during 20-second intervals
in random sequence. Optimized biventricular pacing was finally compared with atrial pacing at a matched heart
rate and to a sinus rhythm during 30-second intervals. Vasoactive medication and fluid infusion rates were held
constant. The arterial pressurewas digitized, recorded, and integrated. Statistical significancewas assessed using
linear mixed effects models and Bonferroni’s correction.
Results: Optimized atrioventricular delay, ranging from 90 to 270 ms, increased the mean arterial pressure 4%
versus nominal and 7% versus the worst (P<.001). Optimized interventricular delay increased pressure 3%
versus nominal and 7% versus the worst. Optimized biventricular pacing increased the mean arterial pressure
4% versus sinus rhythm (78.5  2.4 vs 75.1  2.4 mm Hg; P ¼ .002) and 3% versus atrial pacing (76.4  2.7
mm Hg; P ¼ .017).
Conclusions: Temporary biventricular pacing improves the hemodynamics after chest closure, with effects sim-
ilar to those within 1 hour of bypass. Individualized optimization of atrioventricular delay is warranted, because
the optimal delay was longer in 80% of our patients than the current recommendations for temporary postop-
erative pacing. (J Thorac Cardiovasc Surg 2012;144:1445-52)P
MCardiac resynchronization therapy, or biventricular pacing
(BiVP), has been proven efficacious for the treatment of
chronic heart failure, although its use in acute conditions
is less well established. Currently, permanent BiVP is the
standard of care for patients with medication-refractory se-
vere heart failure with left ventricular (LV) dysfunction and
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The Journal of Thoracic and Carmorbidity and mortality in this population and improves
the LV geometry and function.2-5 BiVP is effective even
in patients with mildly symptomatic (New York Heart
Association class I and II) heart failure with a low
ejection fraction and intraventricular conduction delay,
reducing heart failure events and increasing the interval to
the first hospitalization.6,7
Although BiVP is clinically useful, more than 30% of
implants do not result in objective or subjective benefits.3
Programmable parameters that can be manipulated to opti-
mize BiVP include atrioventricular delay (AVD) and inter-
ventricular delay (VVD). The hemodynamic indexes used
to assess optimization include cardiac output (CO) and
mean arterial pressure (MAP).8-10
The effects of temporary BiVP in low output states af-
ter cardiac surgery have been previously studied.7 Investi-
gation has centered on patients with a low LV ejection
fraction (LVEF) preoperatively, because this measure in-
dependently predicts the risk of acute heart failure.11
The clinical results of these studies have been mixed,
with the greatest benefit observed early after cardiopulmo-
nary bypass (CPB).12,13 BiVP is a promising adjunct
to pharmacologic support after surgery, because it
can improve the stroke volume without increasing
myocardial oxygen consumption.14 Patient selection anddiovascular Surgery c Volume 144, Number 6 1445
Abbreviations and Acronyms
AAI ¼ atrial pacing
AVD ¼ atrioventricular delay
BIPACS ¼ Biventricular Pacing After Cardiac
Surgery
BiVP ¼ biventricular pacing
CO ¼ cardiac output
CPB ¼ cardiopulmonary bypass
LV ¼ left ventricular
LVEF ¼ LV ejection fraction
MAP ¼ mean arterial pressure
VVD ¼ interventricular delay
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Mthe optimal pacing protocols in this setting have not yet
been defined.
The Biventricular Pacing After Cardiac Surgery
(BIPACS) trial is a randomized clinical trial evaluating
the use of an optimized pacing protocol, including
BiVP perioperatively in patients with a low preoperative
LVEF and an intraventricular conduction delay. The
clinical trial registration number was NCT00498940
(http://ClinicalTrials.gov). The primary hypothesis was
that continuous optimized pacing will increase the CO
15% compared with the standard of care. Pacing is opti-
mized at 3 points. Phase I is initiated within 1 hour of wean-
ing from CPB, phase II at the conclusion of surgery, and
phase III 12 to 24 hours later. The phase I substudy analysis
showed that optimization of AVD and VVD independently
increased the CO, as measured by an aortic flow probe. This
was assessed in all patients in the BiVP and control groups,
comparing the effects within each patient rather than be-
tween the patient groups. Optimized BiVP increased the
CO 10% compared with sinus rhythm and 13% compared
with atrial pacing at the same rate, indicating that the hemo-
dynamic benefit was independent of the increased heart
rate.15 However, the preliminary data from our own group,
as well as others, have suggested that the BiVP effects
might not be sustained over time after CPB. Accordingly,
we initiated the present study using data from phase II, after
chest closure. In the absence of direct measures of CO, the
MAP was used as the optimization marker. We hypothe-
sized that BiVP optimization would increase the MAP
and that optimized BiVP would increase the MAP com-
pared with sinus rhythm or atrial pacing.METHODS
BiPACS Study Population
The Columbia University Medical Center institutional review board ap-
proved the study protocol, and the study was conducted under support from
the National Institutes of Health with an investigational device exemption
from the Food and Drug Administration. Adult patients undergoing elec-
tive open heart surgery with CPB are screened for eligibility to enroll in1446 The Journal of Thoracic and Cardiovascular Surthe BiPACS trial. All patients provided written, informed consent. The in-
clusion criteria were preoperative congestive heart failure, LVEF of 40% or
less, and QRS duration of 100 ms or more, or patients undergoing com-
bined mitral and aortic valve surgery. The LVEF and QRS criterion was lib-
eralized from 35% and 120 ms, respectively, in the original protocol. The
exclusion criteria were atrial fibrillation, second- or third-degree atrioven-
tricular block, congenital heart disease, intracardiac shunt, or heart rate
greater than 120 bpm after separation from CPB. The preoperative data ob-
tained by chart review included LVEF, as measured on the echocardiogram
or left ventriculogram; heart rhythm, QRS duration, and intraventricular
block from the electrocardiographic tracings; type of surgery performed;
and demographic characteristics. The BiPACS trial is ongoing and the
study target 206 patients. The study is currently being expanded to the Uni-
versity of California at Los Angeles.Study Design and Optimization Protocol
Patients in the BiPACS trial are randomized to 2 treatment groups at
the end of phase I. To avoid imbalances that can occur using simple ran-
domization, randomly permuted blocks of 4, 6, and 8 are used with a treat-
ment allocation ratio of one, with each group to be of equal size. The
phase II testing described in the present report is performed in all patients
completing phase I and randomized. AVD is optimized first, followed by
the ventricular pacing site, and then VVD. The settings for each individual
optimization parameter are tested in random sequence. The detailed
methods of the protocol have been previously reported.15 Phase I optimi-
zation and testing occur after stabilizing vasoactive drug and volume re-
quirements post-CPB. Standard hemodynamic monitoring, including
systemic and pulmonary arterial pressures and transesophageal echocardi-
ography, are used. Patients completing phase I are then randomized to
continuous BiVP or the standard of care. BiVP patients are paced using
optimized phase I settings until phase II. After closure of the chest and es-
tablishment of stable inotrope and vasopressor dosing, the phase II BiVP
optimization protocol is initiated. The pacing leads are attached to a Med-
tronic InSync III permanent biventricular pacemaker (Medtronic, Inc,
Minneapolis, Minn) mounted in an external housing unit, and their sensing
and pacing functions are tested and confirmed. The use of this pacemaker
for temporary BiVP is under an investigational device exemption from the
Food and Drug Administration. The pacing rate is 90 bpm, or 10 bpm
greater than the patient’s intrinsic heart rate if greater than 90 bpm to
ensure atrial capture, up to a maximum of 120 bpm. The electrocardio-
graphic and arterial pressure signals are collected with an analog-to-
digital converter (PowerLab, ADInstruments, Inc, Milford, Mass) and
recorded on a personal computer (iMac, Apple Computer, Inc, Cupertino,
Calif). The MAP is measured by averaging the digitized arterial pressure
waveforms for 1 respiratory cycle using MacLab software (ADInstru-
ments, Inc) and custom-designed routines in Matlab (MathWorks, Inc,
Natick, Mass).
BiVP optimization is performed by optimization of AVD, followed by
VVD. All pacing settings during optimization are conducted during
20-second intervals and tested twice. Rapid optimization of the cardiac
mechanics over brief intervals has been previously described.8,16,17
Determination of the interatrial delay (atrioventricular conduction
prolongation) was formalized as follows. The intrinsic atrioventricular
interval between atrial and ventricular sensing, with the pacemaker set to
the dual-sensed (ODO) mode, is measured first, using data displayed on
the programmer screen. Next, the interval between the atrial pacing im-
pulse and the sensed ventricular response (paced atrioventricular interval)
is determined, with the pacemaker set to the atrial paced-dual sensed mode
(ADI). The atrioventricular conduction prolongation was determined using
the formula, atrioventricular conduction prolongation ¼ paced atrioven-
tricular interval minus intrinsic atrioventricular interval, and was used to
eliminate any inappropriate AVDs.
AVD optimization was performed during sequential pacing, with
a VVD of 0 ms. The AVD was varied in 30-ms increments (range,gery c December 2012
TABLE 1. Baseline clinical characteristics
Patients (n)
Total 30
Optimization analysis 30
Optimized BiVP vs AAI vs sinus rhythm 21
Age (y) 67  12
LVEF (%) 35  15
QRS duration (ms) 119  24
Male gender (%) 77
Surgery type (n)
CABG/AVR, CABG/MVR, CABG/AVR/MVR 13
AVR/MVR 8
CABG 6
AVR 3
BiVP, Biventricular pacing; AAI, atrial pacing; LVEF, left ventricular ejection frac-
tion; CABG, coronary artery bypass grafting; AVR, aortic valve replacement; MVR,
mitral valve replacement or repair.
Rubinstein et al Perioperative Management90-270), in randomized sequence. AVDs longer than the patient’s intrinsic
paced AVDwere not tested. Based on the average of 2 runs, the AVD yield-
ing the greatest MAP was selected as the optimal AVD. VVD optimization
was performed next using the optimal AVD and varying the VVD in 20-ms
increments, ranging from80 ms (left ventricle first) toþ80 ms (right ven-
tricle first), in randomized order. The MAP, averaged between 2 runs as
a function of VVD, was plotted, and the VVD yielding the greatest MAP
was selected as the optimal VVD. These steps defined the optimal BIVP
protocol for each patient. The phase II optimized BiVP was then comparedFIGURE 1. Representative intraoperative recording demonstrating changes in e
delay (AVD) decreased from 240 to 90 ms in patient 14. Mean arterial pressure (
sequential implementation, by chance, of best and worst AVDs for this patient.
BiPACS, Biventricular Pacing After Cardiac Surgery; HR, heart rate.
The Journal of Thoracic and Carwith the phase I BiVP settings, right atrial pacing (AAI mode) at the same
heart rate, and to normal sinus rhythm (NSR) with no pacing, in random-
ized order, during 30-second intervals. The superior between the phase I
BiVP settings and phase II optimized BiVP was selected as optimum and
used for continuous pacing in the BiVP study group, pending additional op-
timization studies the next day.
The BiPACS trial uses the CO as the primary endpoint, predicated on
the notion that organ flow is the primary determinant of morbidity and sur-
vival after cardiac surgery. We have also demonstrated that optimization of
AVD and VVD during BiVP is based on the ‘‘dose–response curves,’’ in
which the changes in CO could be less than 5% for successive settings. Op-
timally, then, optimization should be based on serial changes in the CO that
can be rapidly and accurately determined for very small changes. Optimi-
zation using our protocol involves measurement of CO for 38 pacemaker
settings. In phase 1, early after CPB, a very narrow window and greater re-
quirement for accuracy for optimization favors flow probe use.15 Accuracy
and speed are critical. However, the flow probe must be removed before
chest closure. Thus, we chose the MAP as a surrogate for CO after chest
closure. Thermal dilution methods were available as an alternative, be-
cause all patients had a pulmonary artery catheter placed; however, the
long response time and extra volume administration for 38 measurements
was considered prohibitive for a measurement with limited accuracy. The
endpoint of the study in phase III, in the intensive care unit, does make use
of thermal dilution, because slower measuring techniques are appropriate.
Statistical Analysis
For AVD and VVD optimization data and for the comparison among
the optimized BiVP, AAI, and NSR, descriptive statistics were calculated
for each group. Differences among multiple groups (3 groups) were testedlectrocardiogram (ECG) and arterial pressure (Art P)when atrioventricular
MAP) decreased immediately from 94 to 86 mm Hg. This change reflected
A similar range of arterial pressures is shown in Figure 2, A, for Patient 8.
diovascular Surgery c Volume 144, Number 6 1447
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Musing a linear mixed effects model. Post hoc comparisons to assess
pairwise differences between groups were performed using the paired
Student t test. Bonferroni’s correction was used to adjust for multiple com-
parisons. The distribution of the optimal AVD (or VVD) settings was an-
alyzed to determine whether it differed from the default setting. Statistical
analysis was performed using SAS, version 9.1 (SAS Institute, Inc,
Cary, NC).
RESULTS
Study Population
The data were acquired in phase II for 44 patients of the
89 enrolled during the recruitment period (April 2007 to
June 2010). BIVP optimization analysis was performed
for 30 patients, with 14 excluded because of frequent ven-
tricular ectopy, an intra-aortic balloon pump, or other fac-
tors affecting the arterial pressure data quality. Nine
additional patients were excluded from the final compari-
son of the optimized BIVP, AAI, and NSR because of atrio-
ventricular block and other factors, limiting the final
comparison group to 21 patients. The baseline clinical char-
acteristics are listed in Table 1. The demographic data were
age, 67  12 years, LVEF 35%  15%, and QRS duration
119 24 ms (mean SD). The proportion of male patients
was 77%. Most underwent valve surgery, either as a dou-
ble/triple valve case (8 patients) or combined valve and cor-
onary artery bypass grafting (13 patients); 6 underwent
isolated coronary artery bypass grafting and 3 underwent
isolated aortic surgery.
Clinical Results
A representative example of the immediate effects of the
transition between 2 AVDs is shown in Figure 1, where
a change in AVD from 240 ms to 90 ms resulted in an abrupt
decrease in arterial pressure. Representative examples of
AVD and VVD optimization are shown in Figure 2, A,B.
The MAP was averaged over 2 runs and plotted to display
the optimal pacing setting for each patient. For the patientFIGURE 2. Representative example of effects of atrioventricular delay (AVD
(MAP). Standard errors of averaged duplicate determinations shown in brac
AVDs according to MAP are labeled. B, Best, worst, and nominal VVDs accord
gery; RV, right ventricle; LV, left ventricle; VVD, interventricular delay.
1448 The Journal of Thoracic and Cardiovascular Surrepresented in Figure 2, an AVD of 240 ms, resulting in
a peak MAP of 105.4 mm Hg, and a VVD ofþ60 ms (right
ventricle first), resulting in a peak MAP of 97.0 mm Hg,
were optimal.
A comparison of the MAP for the optimized, worst, and
nominal (120 ms) AVD settings showed significant differ-
ences among the groups (P<.0001). In pairwise compar-
isons, the MAP was significantly different in the optimal
and worst groups compared with that of the nominal
AVD (P < .001 for both comparisons). The mean
increase in the MAP from the worst AVD to the optimal
AVD was 7% (range, 1%-18%). The mean increase in
the MAP from the nominal to the optimal AVD was 4%
(range, 0%-11%).
Differences in the MAP were significant comparing the
optimal, worst, and nominal (0 ms) VVD settings
(P<.0001). In pairwise comparisons, both the optimal and
worst VVD differed from the nominal VVD (P< .0001
and P ¼ .0005, respectively). The mean increase in the
MAP from the worst VVD to the optimal VVD was 7%
(range, 1%-31%). The mean increase in the MAP from
the nominal to the optimal VVDwas 4% (range, 0%-11%).
The distribution of optimal AVDs is shown in Figure 3.
An AVD of 90 ms was the optimal setting in only 2 patients.
The optimum AVD was 120 ms in 4 patients and was 150
ms or more in 24 patients. The chance of the nominal setting
of 120 ms being optimal was 13% (95% confidence inter-
val, 4%-28%) and the chance of the optimal setting being
longer than 120 ms was 80% (95% confidence interval,
64%-91%). This justified the need for individualized opti-
mization in AVD.
The distribution of optimal VVDs (Figure 4) was fairly
uniform over the settings, with no clear preference of
RV-first versus LV-first pacing. The nominal VVD yielded
the lowest MAP for 5 patients, and the chance of the
default setting being optimal was 17% (95% confidence) and interventricular delay (VVD) optimization on mean arterial pressure
kets. A, Best AVD according to MAP was 240 ms. Worst and nominal
ing to MAP are labeled. BiPACS, Biventricular Pacing After Cardiac Sur-
gery c December 2012
FIGURE 3. Optimized atrioventricular delay (AVD) in 30 patients formed roughly normal distribution around median of 180 ms.
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Minterval, 6%-32%), indicating the need for individualized
optimization in VVD.
A comparison of the hemodynamics of optimized BiVP,
AAI, and NSR is shown in Figure 5. The differences in the
MAP among the 3 groups were significant (P ¼ .0002), as
were the pairwise comparisons between the optimized
BiVP, AAI, and NSR (P ¼ .0036 and P ¼ .0006, respec-
tively). The optimized BiVP resulted in an increase in the
MAP by 3% versus AAI at the same heart rate (MAP,
78.9  2.5 vs 76.4  2.7 mm Hg, mean  SEM) and by
5% versus NSR (75.1  2.4 mm Hg). The increase in the
MAP corresponded with a significant increase in theFIGURE 4. Optimized interventricular delay (VVD) evenly s
The Journal of Thoracic and Carmean diastolic blood pressure by 3% versus AAI (63.8 
2.3 vs 62.2  2.4 mm Hg) and by 6% versus NSR (60.3
 2.3 mm Hg; P ¼ .0043 and P ¼ .0007, respectively).
The systolic blood pressure was unique, because it in-
creased by 4% versus AAI (108.8  3.4 vs 104.5  3.6
mm Hg; P ¼ .0048); however, no significant difference
was found compared with the NSR (105.8  3.1 mm Hg).
This pattern was reflected in the increased pulse pressure
in BiVP by 6% versus AAI (45.1  2.3 vs 42.3  2.1
mmHg) nearing significance (P¼ .0084) and no significant
difference compared with NSR (45.6  2.0 mm Hg). AAI
resulted in a decrease in pulse pressure of 7% versuscattered over full range of values explored in 30 patients.
diovascular Surgery c Volume 144, Number 6 1449
FIGURE 5. Average effect of optimized biventricular pacing (BiVP),
atrial pacing (AAI), and sinus rhythm (NSR) on normalized mean arterial
pressure (MAP) in 30 patients. Error bars depict 1 standard error of
mean. Differences were statistically significant. Absolute values for
MAP and heart rate indicated in bars. HR, Heart rate.
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MNSR (P ¼ .0008). The paced heart rate was greater in the
BiVP and AAI groups (98  2 bpm; mean  SEM) com-
pared with the NSR group (85  3 bpm; P<.0001).
DISCUSSION
A previous substudy from the BIPACS trial demonstrated
that theCO increased during biventricular pacing versus both
AAI and NSRwithin 1 hour of the conclusion of CPB. How-
ever, the benefits of perioperative pacing can change over
time, and the optimal pacing protocol could also change.18,19
Accordingly, the present substudy was undertaken to
determine whether hemodynamic benefit continues after
chest closure. Because the aortic flow probe was not
available in phase II, the hemodynamic index evaluatedFIGURE 6. Right, Paired plots demonstrate effects of sinus rhythm, optimized
arterial pressure (MAP) for individual patients in present study. Data compared
this clinical trial. Square symbols indicate averages with standard errors. Chan
1450 The Journal of Thoracic and Cardiovascular Surwas the MAP. The present results have confirmed the
statistically significant increases in MAP during
biventricular pacing versus both AAI and NSR during
phase II. Furthermore, optimization of both AVD and VVD
independently contributed to hemodynamic benefit.
The mechanisms and techniques of BiVP optimization
are of interest because more than 30% of recipients do
not benefit from BiVP implants. For temporary pacing,
our finding that MAP is useful for optimization is clinically
relevant, because MAP is a preferred hemodynamic index
for anesthesiologists.
Our results have also defined the optimal AVDs and
VVDs, which were far from the common default values.
AVD affects ventricular filling and mitral regurgitation.20
At greater heart rates, AVD optimization gains importance
because of encroachment on the filling time.8 In the dy-
namic state of recovery frommyocardial edema and inflam-
mation after cardiac surgery, default values of 120 to 150ms
might be too short for diastolic filling. Our optimization
data have demonstrated that the MAP increases 7% over
the worst settings and 4% over the default, which translates
roughly to a 14% and 8% change in the CO, respectively.21
Prolongation of the interatrial and atrioventricular conduc-
tion times in the early postoperative period contributes to
the need for long AVDs.
VVD optimization can improve hemodynamics by
reducing the ventricular dyssynchrony associated with
cardiomyopathy and might potentially compensate for
a suboptimal lead position.4,22,23 In this substudy, VVD
optimization using an optimal AVD increased MAP by an
additional 7% compared with the worst setting and 3%
compared with the default. In the case of the 5 patientsbiventricular pacing (BiVP), and atrial pacing (AAI) on normalized mean
with data for effects on cardiac output of phase I from previous substudy of
ges were statistically significant.
gery c December 2012
Rubinstein et al Perioperative Management
P
Mfor whom the default 0 ms VVD was least favorable, the
optimal VVD was 60 ms or greater, suggesting
conduction delays that necessitate optimization. The
practical limitations on the number of parameters that can
be tested prevented simultaneous variation in AVD and
VVD using this protocol; however, these issues will be
addressed in the analysis of data from phase III.
Consistent with our previous study of phase I,15 we found
intrinsic benefit in BiVP, independent of the heart rate dur-
ing skin closure. Optimized BiVP increased the MAP by
3% and 5% compared with AAI and NSR, respectively.
This increase in the MAP compared with the NSR was pre-
dominantly accounted for by the 6% increase in diastolic
blood pressure. Because the testing intervals were brief
and the inotropes and vasoconstrictors were held constant,
it seems unlikely that changes in systemic vascular resis-
tance were an important source of error.21 Compared with
AAI, however, the increase in the MAP had contributions
from the diastolic and systolic pressures both, likely owing
to an increased pulse pressure (and thus stroke volume) with
BiVP. BiVP appears to correct the detriment to pulse pres-
sure of pacing at a greater heart rate while concurrently im-
proving the diastolic pressure.
In our previous study, the hemodynamics of NSR and
AAI were qualitatively similar, and the CO with AAI was
actually (insignificantly) less than with NSR. In the present
study, the MAP with AAI was intermediate between that of
NSR and BiVP, suggesting a trend toward increasing impor-
tance of AAI (Figure 6). This finding is consistent with pre-
vious work by Eberhardt and colleagues13 and by previous
findings from our own laboratory that suggest the effects of
BiVP and AAI are roughly equivalent on the first postoper-
ative day. It therefore appears that the benefits of BiVP on
contractility are most important in the early post-CPB pe-
riod, decreasing in importance with time as the ischemia–
reperfusion injury resolves.
Is the small change in MAP observed in our study clini-
cally important? Increasing the MAP could potentially af-
fect postoperative mortality, stroke, and cardiac
complications.24 The MAP has previously been shown to
correlate positively with the CO, often underestimating in-
creases in CO.21 Our experience in comparing the hemody-
namic benefits has been that the percentage of changes in
the MAP are roughly one half those measured by CO
when both indexes are used simultaneously. For example,
we recently reported a 10% increase in CO when BiVP
was compared with NSR; the corresponding increase in
the MAP was 5%.15 If the 4% improvement in the MAP
for BiVP versus NSR reported in the present study corre-
sponds to an 8% increase in CO, as we believe, the im-
provement in CO after chest closure would be similar to
that previously reported in phase I.
We have not yet determined whether reoptimization after
chest closure is necessary or if the phase I protocol would beThe Journal of Thoracic and Caradequate for overnight pacing. Given the dynamic early pe-
riod of cardiac recovery from ischemia and reperfusion, re-
optimization during skin closure might prove essential.
Although this trial was directed at optimization of CO, op-
timization in phase II, using the MAP, has emerged as most
important in the clinical outcome of this trial. Phase II op-
timization commonly changes the pacing parameters de-
fined in phase I and remained in effect in the BiVP group
for 12 to 24 hours during the first postoperative night. In
contrast, the phase I protocol is used for 1 to 2 hours, and
the phase III protocol is not used at all for extended pacing.
Nevertheless, preliminary data have demonstrated the clin-
ical benefits of the phase II protocol for both the vasocon-
strictor inotrope score and urine output during the first
postoperative night in the BiVP group compared with the
standard of care group.25
The BiPACS protocol requires 206 completed studies for
sufficient statistical power to demonstrate a 15% benefit in
thermal dilution CO for the BiVP group. We have been ex-
ceptionally fortunate to have received National Institutes of
Health R01 grant support for the present study. Given the
current realities of National Institutes of Health funding,
however, the trial might have to be terminated before reach-
ing its ultimate goal. Premature termination of the BiPACS
trial will make the determination of secondary end points
problematic, including patient selection, relevance of trans-
esophageal echocardiography for defining the optimal can-
didates, importance of the pacing site, and the effects on
morbidity, mortality, and hospital costs.CONCLUSIONS
Optimization of temporary BiVP after chest closure in-
creases the MAP in selected patients. Optimization of
both AVD and VVD contribute to the benefit, and optimized
BiVP is superior to AAI or sinus rhythm. Optimization
should be performed routinely when using temporary
BiVP, and determination of the arterial pressure is a promis-
ing, less-invasive, technique. In view of the broad scatter of
the optimum AVD, individual optimization is warranted, in
preference to default values.
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and the Columbia University Division of Cardiothoracic Surgery
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preparation.References
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